Opko Health (OPK) Cash & Equivalents (2010 - 2026)

Opko Health (OPK) has 17 years of Cash & Equivalents data on file, last reported at $300.8 million in Q2 2026.

• Quarterly Cash & Equivalents rose 10.69% year-over-year to $300.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $300.8 million (up 10.69% YoY) and the FY2025 annual result came in at $369.1 million, down 14.55% from the prior year.
• Cash & Equivalents retreated to $300.8 million in Q2 2026, from $341.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $436.0 million in Q1 2025 to a low of $40.6 million in Q2 2024.
• A 5-year average of $232.7 million and a median of $195.6 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 62.47% — and 2025, when it surged 569.65%.
• Tracing OPK's Cash & Equivalents over 5 years: stood at $153.2 million in 2022, then sank by 37.41% to $95.9 million in 2023, then soared by 350.49% to $431.9 million in 2024, then dropped by 14.55% to $369.1 million in 2025, then slipped by 18.51% to $300.8 million in 2026.
• The last three Cash & Equivalents figures came in at $300.8 million (Q2 2026), $341.9 million (Q1 2026), and $369.1 million (Q4 2025), per Business Quant data.